Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K
Antifungal Agents01:15

Antifungal Agents

106
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
106
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K
Inhaled Medications01:23

Inhaled Medications

1.1K
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
1.1K
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

2.1K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
2.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.5K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled Trials.

Pulmonary therapy·2026
Same author

Authors' response.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Appropriate Use of Single Inhaled Triple Therapy in Uncontrolled Asthma: A Multinational Modified Delphi Consensus.

Journal of asthma and allergy·2026
Same author

Small Airway Dysfunction May Mediate the Association Between Body Mass Index and Severe Asthma Exacerbations.

The European respiratory journal·2026
Same author

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.

Lancet (London, England)·2026
Same author

Clinical remission in allergy and clinical immunology practice: State of the art and World Allergy Organization (WAO) call to action.

The World Allergy Organization journal·2026

Related Experiment Video

Updated: Apr 20, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

11.2K

Antifungals in severe asthma.

Amit D Parulekar1, Zuzana Diamant, Nicola A Hanania

  • 1aSection of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, Texas, USA bDepartment of Respiratory Medicine and Allergology, Skäne University Hospital, Sweden cDepartment of General Practice & QPS-NL, Groningen, the Netherlands.

Current Opinion in Pulmonary Medicine
|November 22, 2014
PubMed
Summary

Antifungal therapy may benefit severe asthma patients with fungal allergy, but more research is needed. Current evidence supports use in allergic bronchopulmonary aspergillosis (ABPA) but not routinely in severe asthma with fungal sensitization (SAFS).

More Related Videos

Quantifying the Antifungal Activity of Peptides Against Candida albicans
06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

3.1K
Assessing Anti-fungal Activity of Isolated Alveolar Macrophages by Confocal Microscopy
09:04

Assessing Anti-fungal Activity of Isolated Alveolar Macrophages by Confocal Microscopy

Published on: July 9, 2014

12.0K

Related Experiment Videos

Last Updated: Apr 20, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

11.2K
Quantifying the Antifungal Activity of Peptides Against Candida albicans
06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

3.1K
Assessing Anti-fungal Activity of Isolated Alveolar Macrophages by Confocal Microscopy
09:04

Assessing Anti-fungal Activity of Isolated Alveolar Macrophages by Confocal Microscopy

Published on: July 9, 2014

12.0K

Area of Science:

  • Pulmonology
  • Allergy and Immunology
  • Infectious Diseases

Background:

  • Severe asthma often remains uncontrolled despite standard treatments.
  • Fungal allergy is increasingly implicated in severe asthma pathogenesis.
  • Limited evidence exists for treating fungal asthma.

Purpose of the Study:

  • To review evidence on antifungal agents for allergic bronchopulmonary aspergillosis (ABPA) and severe asthma with fungal sensitization (SAFS).
  • To identify areas for future research in fungal asthma treatment.

Main Methods:

  • Systematic review of existing literature on antifungal therapy in ABPA and SAFS.
  • Analysis of studies evaluating oral triazole therapy.

Main Results:

  • Oral triazole therapy shows promise in ABPA but yields mixed results in SAFS.
  • Limited data suggest potential benefits in symptom control, lung function, and reduced corticosteroid use.
  • Optimal patient selection and treatment parameters remain undefined.

Conclusions:

  • The role of antifungal therapy in severe asthma is not yet clear.
  • Routine use in severe asthma without ABPA is not recommended.
  • Further research is essential to define the utility and identify patient subgroups who benefit from antifungal medications.